Transarterial radioembolization for hepatocellular carcinoma: a review

References

• El-SeragHBRudolphKLHepatocellular carcinoma: epidemiology and molecular carcinogenesisGastroenterology200713272557257617570226
   PubMed Web of Science ®Google Scholar
• OzenneVBouattourMGouttéNProspective evaluation of the management of hepatocellular carcinoma in the elderlyDig Liver Dis201143121001100521798829
   PubMedGoogle Scholar
• LozanoRNaghaviMForemanKGlobal and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010Lancet201238098592095212823245604
   PubMed Web of Science ®Google Scholar
• GBD 2013 Risk Factors CollaboratorsForouzanfarMHAlexanderLGlobal, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013Lancet2015386100102287232326364544
   PubMed Web of Science ®Google Scholar
• MazzantiRArenaUTassiRHepatocellular carcinoma: where are we?World J Exp Med201661213626929917
   PubMedGoogle Scholar
• BodzinASBusuttilRWHepatocellular carcinoma: advances in diagnosis, management, and long term outcomeWorld J Hepatol2015791157116726019732
   PubMed Web of Science ®Google Scholar
• KangTWRhimHRecent advances in tumor ablation for hepatocellular carcinomaLiver Cancer20154317618726674766
   PubMed Web of Science ®Google Scholar
• WooHYHeoJTransarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: now and futureClin Mol Hepatol201521434434826770921
   PubMedGoogle Scholar
• RaoulJLSangroBFornerAEvolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolizationCancer Treat Rev201137321222020724077
   PubMed Web of Science ®Google Scholar
• SangroBSalemRKennedyAColdwellDWasanHRadioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendationsAm J Clin Oncol201134442243120622645
   PubMed Web of Science ®Google Scholar
• GarinELenoirLRollandYDosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary resultsJ Nucl Med201253225526322302962
   PubMed Web of Science ®Google Scholar
• ChiesaCMaccauroMRomitoRNeed, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of MilanQ J Nucl Med Mol Imaging201155216819721386789
   PubMed Web of Science ®Google Scholar
• LauWYKennedyASKimYHPatient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheresInt J Radiat Oncol Biol Phys201282140140720950954
   PubMed Web of Science ®Google Scholar
• ArielIMPackGTTreatment of inoperable cancer of the liver by intra-arterial radioactive isotopes and chemotherapyCancer19672057938046024291
   PubMed Web of Science ®Google Scholar
• BlanchardRJGrotenhuisILafaveJWFryeCWPerryJFTreatment of experimental tumors; utilization of radioactive microspheresArch Surg19648940641014160169
   PubMed Web of Science ®Google Scholar
• SalemRLewandowskiRJMulcahyMFRadioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomesGastroenterology20101381526419766639
   PubMed Web of Science ®Google Scholar
• SangroBCarpaneseLCianniREuropean Network on Radio-embolization with Yttrium-90 Resin Microspheres (ENRY)Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluationHepatology201154386887821618574
   PubMed Web of Science ®Google Scholar
• HilgardPHamamiMFoulyAERadioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and longterm survivalHepatology20105251741174921038413
   PubMed Web of Science ®Google Scholar
• KulikLMCarrBIMulcahyMFSafety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosisHepatology2008471718118027884
   PubMed Web of Science ®Google Scholar
• BesterLMetelingBBoshellDChuaTCMorrisDLTransarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: a review of the literatureJ Med Imaging Radiat Oncol201458334135224589204
   PubMed Web of Science ®Google Scholar
• CoveyAMBrodyLAMaluccioMAGetrajdmanGIBrownKTVariant hepatic arterial anatomy revisited: digital subtraction angiography performed in 600 patientsRadiology2002224254254712147854
   PubMed Web of Science ®Google Scholar
• IlhanHGoritschanAPaprottkaPSystematic evaluation of tumoral 99mTc-MAA uptake using SPECT and SPECT/CT in 502 patients before 90Y radioembolizationJ Nucl Med201556333333825655623
   PubMed Web of Science ®Google Scholar
• HoSLauWYLeungTWChanMJohnsonPJLiAKClinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancerEur J Nucl Med19972432932989143467
   PubMedGoogle Scholar
• MDS NordionTheraSphere® Yttrium-90 Glass Microspheres US [package insert]USAMDS Nordion2007
   Google Scholar
• Sirtex MedicalIR-Spheres® Training Program: Physicians and InstitutionsLane CoveSirtex Medical
   Google Scholar
• LamMGGorisMLIagaruAHMittraESLouieJDSzeDYPrognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECTJ Nucl Med201354122055206124144563
   PubMed Web of Science ®Google Scholar
• JakobsTFSaleemSAtassiBFibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheresDig Dis Sci20085392556256318231857
   PubMed Web of Science ®Google Scholar
• SangroBGil-AlzugarayBRodriguezJLiver disease induced by radioembolization of liver tumors: description and possible risk factorsCancer200811271538154618260156
   PubMed Web of Science ®Google Scholar
• AtassiBBangashAKLewandowskiRJBiliary sequelae following radioembolization with yttrium-90 microspheresJ Vasc Interv Radiol200819569169718440457
   PubMed Web of Science ®Google Scholar
• KennedyASColdwellDNuttingCResin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experienceInt J Radiat Oncol Biol Phys200665241242516690429
   PubMed Web of Science ®Google Scholar
• MurthyRXiongHNunezRYttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary resultsJ Vasc Interv Radiol200516793794516002501
   PubMed Web of Science ®Google Scholar
• MurthyRBrownDBSalemRGastrointestinal complications associated with hepatic arterial yttrium-90 microsphere therapyJ Vasc Interv Radiol200718455356117446547
   PubMed Web of Science ®Google Scholar
• SzyszkoTAl-NahhasATaitPManagement and prevention of adverse effects related to treatment of liver tumours with 90Y microspheresNucl Med Commun2007281212417159545
   PubMed Web of Science ®Google Scholar
• LeungTWLauWYHoSKRadiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumorsInt J Radiat Oncol Biol Phys19953349199247591903
   PubMed Web of Science ®Google Scholar
• SalemRParikhPAtassiBIncidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distributionAm J Clin Oncol200831543143818838878
   PubMed Web of Science ®Google Scholar
• SalemRThurstonKGRadioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerationsJ Vasc Interv Radiol20061781251127816923973
   PubMed Web of Science ®Google Scholar
• JelicSSotiropoulosGCESMO Guidelines Working GroupHepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201021suppl 5v59v6420555104
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN) [webpage on the Internet]National Comprehensive Cancer Network Clinical Practice Guidelines in OncologyHepatobiliary Guidelines. V22010 Available from: http://www.nccn.org/professionals/physician_gls/PDF/hepatobiliary.pdfAccessed December 30, 2015
   Google Scholar
• ThomasMBJaffeDChotiMMHepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning MeetingJ Clin Oncol201028253994400520679622
   PubMed Web of Science ®Google Scholar
• KulikLMAtassiBvan HolsbeeckLYttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantationJ Surg Oncol200694757258617048240
   PubMed Web of Science ®Google Scholar
• LencioniRLoco-regional treatment of hepatocellular carcinomaHepatology201052276277320564355
   PubMed Web of Science ®Google Scholar
• PiscagliaFBolondiLThe intermediate hepatocellular carcinoma stage: should treatment be expanded?Dig Liver Dis201042suppl 3S258S26320547312
   PubMedGoogle Scholar
• SalemRLewandowskiRJKulikLRadioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinomaGastroenterology20111402497.e2507.e221044630
   PubMed Web of Science ®Google Scholar
• KoobyDAEgnatashviliVSrinivasanSComparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinomaJ Vasc Interv Radiol201021222423020022765
   PubMed Web of Science ®Google Scholar
• CarrBIKondraguntaVBuchSCBranchRATherapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort studyCancer201011651305131420066715
   PubMed Web of Science ®Google Scholar
• Moreno-LunaLEYangJDSanchezWEfficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinomaCardiovasc Intervent Radiol201336371472323093355
   PubMed Web of Science ®Google Scholar
• El FoulyAErtleJEl DorryAIn intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?Liver Int201535262763525040497
   PubMed Web of Science ®Google Scholar
• GramenziAGolfieriRMosconiCBLOG (Bologna Liver Oncology Group)Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysisLiver Int20153531036104724750853
   PubMed Web of Science ®Google Scholar
• IñarrairaeguiMPardoFBilbaoJIResponse to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinomaEur J Surg Oncol201238759460122440743
   PubMed Web of Science ®Google Scholar
• de la TorreMBuades-MateuJde la RosaPAA comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenibLiver Int Epub2016222
   Web of Science ®Google Scholar
• LewandowskiRJKulikLMRiazAA comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemo-embolization versus radioembolizationAm J Transplant2009981920192819552767
   PubMed Web of Science ®Google Scholar
• VoucheMLewandowskiRJAtassiRRadiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resectionJ Hepatol20135951029103623811303
   PubMed Web of Science ®Google Scholar
• GabaRCLewandowskiRJKulikLMRadiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolizationAnn Surg Oncol20091661587159619357924
   PubMed Web of Science ®Google Scholar
• GallePBlancJVan LaethemJLEfficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and prior anti-tumor therapy: a subanalysis from the SHARP trialJ Hepatol200848S372
   Web of Science ®Google Scholar
• BruixJRaoulJLShermanMEfficacy and safety of sorafenib in patients with hepatocellular carcinoma (HCC): subanalysis of Sharp trial based on Barcelona Clinic Liver Cancer (BCLC) stageJ Hepatol200950S28S29
   Web of Science ®Google Scholar
• ChengALKangYKChenZEfficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialLancet Oncol2009101253419095497
   PubMed Web of Science ®Google Scholar
• LlovetJMRicciSMazzaferroVSorafenib in advanced hepatocellular carcinomaN Engl J Med2008359437839018650514
   PubMed Web of Science ®Google Scholar
• RickeJBullaKKolligsFSafety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMICLiver Int201535262062624930619
   PubMed Web of Science ®Google Scholar
• MazzaferroVSpositoCBhooriSYttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 studyHepatology20135751826183722911442
   PubMed Web of Science ®Google Scholar
• GarinELenoirLEdelineJBoosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising conceptEur J Nucl Med Mol Imaging20134071057106823613103
   PubMed Web of Science ®Google Scholar
• WoodallCEScogginsCREllisSFIs selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis?J Am Coll Surg2009208337538219317999
   PubMed Web of Science ®Google Scholar
• AtassiBBangashAKBahraniAMultimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essayRadiographics2008281819918203932
   PubMed Web of Science ®Google Scholar
• RiazARyuRKKulikLMAlpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radio-logic response, progression, and survivalJ Clin Oncol200927345734574219805671
   PubMed Web of Science ®Google Scholar
• ChanSLMoFKJohnsonPJNew utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapyJ Clin Oncol200927344645219064965
   PubMed Web of Science ®Google Scholar
• LencioniRLlovetJMModified RECIST (mRECIST) assessment for hepatocellular carcinomaSemin Liver Dis2010301526020175033
   PubMed Web of Science ®Google Scholar
• RiazAKulikLLewandowskiRJRadiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheresHepatology20094941185119319133645
   PubMed Web of Science ®Google Scholar
• MonskyWLGarzaASKimITreatment planning and volumetric response assessment for Yttrium-90 radioembolization: semiautomated determination of liver volume and volume of tumor necrosis in patients with hepatic malignancyCardiovasc Intervent Radiol201134230631820683722
   PubMed Web of Science ®Google Scholar
• GaliziaMSTöreHGChalianHMcCarthyRSalemRYaghmaiVMDCT necrosis quantification in the assessment of hepatocellular carcinoma response to yttrium 90 radioembolization therapy: comparison of two-dimensional and volumetric techniquesAcad Radiol2012191485422054801
   PubMed Web of Science ®Google Scholar